An update on the use of indacaterol in patients with COPD
Current guidelines for the management of chronic obstructive pulmonary disease (COPD) establish that bronchodilator medications are central to the symptomatic treatment of the disease. Regular treatment with long-acting bronchodilators is recommended as more effective and convenient than short-actin...
Main Authors: | Nadia S. Brienza, Óscar Amor-Carro, David Ramos-Barbón |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2011-02-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465810387810 |
Similar Items
-
Effectiveness of Indacaterol-Glycopyrronium in preventing COPD exacerbations in comparison to Salmeterol-Fluticasone
by: Shamim Ahmed, et al.
Published: (2022-02-01) -
A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study
by: Juvelekian G, et al.
Published: (2015-10-01) -
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
by: Horita N, et al.
Published: (2015-04-01) -
Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
by: Price, D, et al.
Published: (2011) -
Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)